PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy

The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients undergoing these immunotherapy treatments, the only clinically accepted biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales: Bocanegra, Ana, Blanco, Ester, Fernandez-Hinojal, Gonzalo, Arasanz, Hugo, Chocarro, Luisa, Zuazo, Miren, Morente, Pilar, Vera, Ruth, Escors, David, Kochan, Grazyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460585/
https://www.ncbi.nlm.nih.gov/pubmed/32824655
http://dx.doi.org/10.3390/ijms21165918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460585/
https://www.ncbi.nlm.nih.gov/pubmed/32824655
http://dx.doi.org/10.3390/ijms21165918

Ejemplares similares